The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study

Koska, J., Ortega, E., Bunt, J. C., Gasser, A., Impson, J., Hanson, R. L., Forbes, J., de Courten, B. and Krakoff, J. (2009) The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. Diabetologia, 52 3: 385-393. doi:10.1007/s00125-008-1239-x


Author Koska, J.
Ortega, E.
Bunt, J. C.
Gasser, A.
Impson, J.
Hanson, R. L.
Forbes, J.
de Courten, B.
Krakoff, J.
Title The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study
Journal name Diabetologia   Check publisher's open access policy
ISSN 0012-186X
1432-0428
Publication date 2009-03-01
Year available 2009
Sub-type Article (original research)
DOI 10.1007/s00125-008-1239-x
Open Access Status Not Open Access
Volume 52
Issue 3
Start page 385
End page 393
Total pages 9
Place of publication Heidelberg, Germany
Publisher Springer
Language eng
Formatted abstract
Aim/hypothesis

Low-grade inflammation may contribute to obesity-related insulin resistance and has been associated with increased risk of type 2 diabetes mellitus. The present study evaluated whether treatment with salsalate, a traditional anti-inflammatory medication, would improve insulin action in obese non-diabetic individuals.

Methods

The study was a randomised, double-blind, placebo-controlled, parallel trial conducted at the inpatient clinical research unit of the NIDKK (Phoenix, AZ, USA). Participants were 54 adults (18 to 45 years of age) with BMI ≥ 30 kg/m2. The intervention was salsalate (3 g/day, n = 28) or identical placebo (n = 26) for 7 days. The allocation was kept concealed by giving the investigator only a number corresponding to a vial of placebo or salsalate sequentially randomised in blocks by sex. Main outcomes were changes in insulin action assessed as rate of glucose disposal (R d) by euglycaemic–hyperinsulinaemic clamp (insulin infusion rate 40 mU m−2 min−1) and glucose tolerance by 75 g OGTT.

Results

The study was completed by 47 participants, of which 40 were analysed (salsalate n = 22, placebo n = 18). Salsalate treatment resulted in decreased fasting plasma glucose concentration (mean [SD]; 4.83 [0.28] vs 5.11 [0.33] mmol/l, p = 0.001) and glucose AUC during the OGTT (p = 0.01), and in increased R d (20 [8] vs 18 [6] µmol [kg estimated metabolic body size]−1 min−1, p = 0.002), while there was no significant change in these variables with placebo (p > 0.3 for all). The effect of salsalate on R d disappeared (p = 0.9) after normalising to increased insulin concentrations (701 [285] vs 535 [201] pmol/l, p < 0.0001) measured during the clamp. No side effects of salsalate were observed during the study.

Conclusions/interpretation

The glucose-lowering potential of salicylates appears to be due to effects on insulin concentration rather than improved insulin action. Salicylate-based compounds may be useful for the treatment and prevention of type 2 diabetes.
Keyword Clinical science
Cytokines
Human
Insulin sensitivity and resistance
Prediction and prevention of type 2 diabetes
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: Mater Research Institute-UQ (MRI-UQ)
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 73 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 89 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 05 Jan 2015, 22:29:12 EST by Ms Kate Rowe on behalf of Mater Research Institute-UQ